1. Immunology/Inflammation
  2. Tim3
  3. ML-T7

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.

For research use only. We do not sell to patients.

ML-T7 Chemical Structure

ML-T7 Chemical Structure

CAS No. : 459789-75-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 215 In-stock
Solution
10 mM * 1 mL in DMSO USD 215 In-stock
Solid
5 mg USD 193 In-stock
10 mg USD 290 In-stock
25 mg USD 580 In-stock
50 mg USD 870 In-stock
100 mg USD 1220 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1].

In Vitro

ML-T7(10 μM, 0-6 days) enhances TCR/STAT5 signaling and promotes CD8+ cell antitumor activity through Tim-3[1].
ML-T7(10 μM, 24 h) promotes DC maturation and function through Tim-3 and Tim-4, enhances DC antigen-presenting ability[1].
ML-T7(10 μM, 24 h) enhances CTL activation and cytokine production, decreases apoptosis of CTLs[1].
ML-T7(10 μM, 48 h) significantly enhances the production of IFN-γ, TNF-α, CD107a, and granzyme B in human NK cell line NK92 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: CD8+ cell
Concentration: 10 μM
Incubation Time: 0-6 days
Result: Increased the phosphorylation of phospholipase C–γ1(PLC-γ1), ZAP70, LCK, ERK1/2, and STAT5 upon anti-CD3/CD28 stimulation.

Cell Invasion Assay[1]

Cell Line: Bone Marrow Cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Increased the expression of DC maturation markers.
In Vivo

ML-T7 (10-50 mg/kg; Intraperitoneal injection; every 2 days, 10 times) inhibits the growth of tumor and prolongs survival of HCC mice, without adverse effects on mice body weight[1].
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 10-week-old mice with spontaneous orthotopic HCC[1]
Dosage: 10-50 mg/kg
Administration: Intraperitoneal injection (i.p.), every 2 days, 10 times
Result: Increased CD8+ T cells in both tumor and spleen. Inhibited T cell exhaustion. Promoted the function of CTLs, NK cells, and DCs.
Animal Model: 10-week-old mice with orthotopic Akt/c-Myc HCC[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.), every 2 days, 10 times
Result: Indicated stronger antituomr activity when treated with ML-T7 and Nivolumab (HY-P9903A). Rejuvenated NK cells by the combination therapy. Inhibited the accumulation of MDSCs and Tregs.
Molecular Weight

506.33

Formula

C27H17Cl2NO5

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C2=C(C(C13OC(C4C(N(C5=CC=C(C=C5Cl)Cl)C(C43)=O)=O)C6=CC=C(C)C=C6)=O)C=CC=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 66.67 mg/mL (131.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9750 mL 9.8750 mL 19.7500 mL
5 mM 0.3950 mL 1.9750 mL 3.9500 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9750 mL 9.8750 mL 19.7500 mL 49.3749 mL
5 mM 0.3950 mL 1.9750 mL 3.9500 mL 9.8750 mL
10 mM 0.1975 mL 0.9875 mL 1.9750 mL 4.9375 mL
15 mM 0.1317 mL 0.6583 mL 1.3167 mL 3.2917 mL
20 mM 0.0987 mL 0.4937 mL 0.9875 mL 2.4687 mL
25 mM 0.0790 mL 0.3950 mL 0.7900 mL 1.9750 mL
30 mM 0.0658 mL 0.3292 mL 0.6583 mL 1.6458 mL
40 mM 0.0494 mL 0.2469 mL 0.4937 mL 1.2344 mL
50 mM 0.0395 mL 0.1975 mL 0.3950 mL 0.9875 mL
60 mM 0.0329 mL 0.1646 mL 0.3292 mL 0.8229 mL
80 mM 0.0247 mL 0.1234 mL 0.2469 mL 0.6172 mL
100 mM 0.0197 mL 0.0987 mL 0.1975 mL 0.4937 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ML-T7 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ML-T7
Cat. No.:
HY-163028
Quantity:
MCE Japan Authorized Agent: